
Exponent stock closed at US$80.17 on Friday, up 2.4% on the day, as traders reacted quickly to fresh Q3 2026 figures. The headline was clean and simple. Net revenue climbed to US$153.1m and diluted earnings per share reached US$0.64, both higher than a year ago.
In the short term, the move looks like a routine relief rally. The more important story is in the trajectory behind it, with double digit growth in both net revenues and earnings intersecting with a premium P/E and a business increasingly tied to complex engineering and scientific work that plays out over many years.
Like Exponent's double digit revenue and earnings gains but uneasy about paying a premium P/E in such a specialised niche? Benchmark this Q3 2026 report against our 30 high quality undervalued stocks.
Earnings tell you how Q3 2026 looked on the income statement, but investors who care about what they are paying for Exponent focus heavily on the cash coming through the door and what sticks. Looking at Exponent's cash flows and applying a discounted cash flow lens, the stock could be a hefty 41% undervalued.
The optimistic view hinges on Exponent turning complex, cross disciplinary work into richer project economics backed by a deep expert bench.
"The main requirement for this thesis is that Exponent continues to attract and retain top-tier PhD talent despite higher stock-based compensation and rising people-related costs, so the firm can service increasingly complex, multidisciplinary engagements."
Q3 results show that hypothesis under pressure testing well. Technical headcount rose 4% while billable hours grew about 8%, and utilization reached 76.7%. Realized rates increased roughly 4% and EBITDA margin on net revenues edged higher to 29.4%, even with stock based pay of US$6.7m.
One Narrative disagrees with today's price. → See where this Narrative says Exponent should trade.
The bearish worry centers on Exponent’s rising structural costs swallowing profit even when work is plentiful.
"Bearish analysts expect Exponent's rising operating expenses, including higher general and administrative costs and stock-based compensation, to keep pressuring margins even when revenue growth is healthy."
Q3 shows that concern only partly landing. Stock based comp reached US$6.7m and full year guidance of about US$28.1m to US$28.4m confirms the expense overhang. Yet EBITDA margin on net revenues moved to 29.4% and management now expects 28% to 28.3% for 2026. That sits above 2025’s 27.6%, so margin squeeze is not evident this quarter, but cost discipline still needs to survive a softer Q4 utilization guide.
Exponent just showed how a solid operating story can still leave investors debating what they are paying for it. The real opportunity is finding stocks that could be undervalued before the market corrects them.
Those are three of them. See every one of the 30 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com